+
Torrent Pharma Seeks CCI Approval for Rs 195 Billion JB Chemicals Deal
ECONOMY & POLICY

Torrent Pharma Seeks CCI Approval for Rs 195 Billion JB Chemicals Deal

Ahmedabad-based Torrent Pharmaceuticals has sought clearance from the Competition Commission of India (CCI) to acquire a majority stake in J B Chemicals and Pharmaceuticals in a Rs 195 billion deal.
Upon completion, Torrent Pharmaceuticals will become India’s second most valuable pharmaceutical company.
The move follows Torrent’s June announcement to acquire a majority stake in J B Chemicals for Rs 195 billion.
“The proposed combination pertains to the acquisition of shareholding by Torrent Pharmaceuticals Ltd in J B Chemicals & Pharmaceuticals Ltd, followed by the merger of the target with the acquirer,” stated a notice filed with the CCI.
Torrent Pharmaceuticals, the flagship company of the Torrent Group, manufactures and sells pharmaceutical formulations across multiple therapeutic segments.
J B Chemicals & Pharmaceuticals is involved in manufacturing and marketing a wide range of formulations and active pharmaceutical ingredients (APIs), and also provides contract development and manufacturing organisation (CDMO) services.
The companies acknowledged horizontal overlaps in certain markets related to the manufacture and sale of pharmaceutical formulations in India.
In June, Torrent agreed to acquire 46.39 per cent stake from promoters Tau Investment Holdings Pte Ltd, an affiliate of global investment firm KKR, for around Rs 119.17 billion. Additionally, it will buy a further 2.80 per cent stake from certain JB Chemicals employees at Rs 1,600 per share, amounting to Rs 7.19 billion.
Following these purchases, Torrent will launch an open offer to acquire 26 per cent from the open market at Rs 1,639.18 per share, totalling Rs 68.43 billion, as per stock exchange norms.
This will be the second largest deal in the Indian pharmaceutical sector, after Sun Pharmaceutical Industries’ 2015 acquisition of Ranbaxy Laboratories. After the share purchase, JB Chemicals will merge into Torrent.
KKR had initially acquired a 65 per cent stake in JB Chemicals in 2020. Earlier this year, in March, KKR divested 5.8 per cent of its stake in JB Chemicals for Rs 14.6 billion via open market transactions.
Founded in 1976, JB Chemicals produces pharmaceuticals in areas including gastroenterology, dermatology and diabetes.
Torrent Pharmaceuticals, with annual revenues exceeding Rs 115 billion, is the flagship company of the Torrent Group, which generates group revenues of Rs 450 billion.
In a comparable major transaction, Sun Pharma announced in April 2014 its plan to acquire rival Ranbaxy for USD 4 billion in an all-stock deal, including USD 800 million in debt. The merger was completed after receiving regulatory approvals in March 2015.
Another significant recent deal saw Mankind Pharma acquire Bharat Serums and Vaccines last year for Rs 138 billion. 

Ahmedabad-based Torrent Pharmaceuticals has sought clearance from the Competition Commission of India (CCI) to acquire a majority stake in J B Chemicals and Pharmaceuticals in a Rs 195 billion deal.Upon completion, Torrent Pharmaceuticals will become India’s second most valuable pharmaceutical company.The move follows Torrent’s June announcement to acquire a majority stake in J B Chemicals for Rs 195 billion.“The proposed combination pertains to the acquisition of shareholding by Torrent Pharmaceuticals Ltd in J B Chemicals & Pharmaceuticals Ltd, followed by the merger of the target with the acquirer,” stated a notice filed with the CCI.Torrent Pharmaceuticals, the flagship company of the Torrent Group, manufactures and sells pharmaceutical formulations across multiple therapeutic segments.J B Chemicals & Pharmaceuticals is involved in manufacturing and marketing a wide range of formulations and active pharmaceutical ingredients (APIs), and also provides contract development and manufacturing organisation (CDMO) services.The companies acknowledged horizontal overlaps in certain markets related to the manufacture and sale of pharmaceutical formulations in India.In June, Torrent agreed to acquire 46.39 per cent stake from promoters Tau Investment Holdings Pte Ltd, an affiliate of global investment firm KKR, for around Rs 119.17 billion. Additionally, it will buy a further 2.80 per cent stake from certain JB Chemicals employees at Rs 1,600 per share, amounting to Rs 7.19 billion.Following these purchases, Torrent will launch an open offer to acquire 26 per cent from the open market at Rs 1,639.18 per share, totalling Rs 68.43 billion, as per stock exchange norms.This will be the second largest deal in the Indian pharmaceutical sector, after Sun Pharmaceutical Industries’ 2015 acquisition of Ranbaxy Laboratories. After the share purchase, JB Chemicals will merge into Torrent.KKR had initially acquired a 65 per cent stake in JB Chemicals in 2020. Earlier this year, in March, KKR divested 5.8 per cent of its stake in JB Chemicals for Rs 14.6 billion via open market transactions.Founded in 1976, JB Chemicals produces pharmaceuticals in areas including gastroenterology, dermatology and diabetes.Torrent Pharmaceuticals, with annual revenues exceeding Rs 115 billion, is the flagship company of the Torrent Group, which generates group revenues of Rs 450 billion.In a comparable major transaction, Sun Pharma announced in April 2014 its plan to acquire rival Ranbaxy for USD 4 billion in an all-stock deal, including USD 800 million in debt. The merger was completed after receiving regulatory approvals in March 2015.Another significant recent deal saw Mankind Pharma acquire Bharat Serums and Vaccines last year for Rs 138 billion. 

Next Story
Infrastructure Transport

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Next Story
Infrastructure Urban

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Next Story
Infrastructure Urban

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Open In App